The Editors’ Choice
Treatment options for itch are limited. Antihistamines represent the most widely available class of antipruritic drugs, with over $2 billion in sales per year for itch alone. However, antihistamines exhibit poor efficacy in most chronic itch conditions, even those associated with the histaminergic itch pathway like urticaria. Thus, itch is often classified dichotomously as either histaminergic or nonhistaminergic in nature. In this issue, Trier et al (p 852) provide evidence that suggests that Researchers